



EUSA Pharma Announces Acquisition of Global Rights to Next Generation Oncology Supportive Care Product Arcoral® Tab from Arcoral Pharma

HEMEL HEMPSTEAD, England and HOKKSUND, Norway – 12 April 2016 – EUSA Pharma (EUSA), a recently-established specialty pharmaceutical company with a focus on oncology and oncology supportive care, today announced the acquisition of the global rights to a next generation formulation of EUSA's current Caphosol® product from Arcoral Pharma AS. The product, Arcoral® Tab, which EUSA plans to rebrand under the Caphosol® name, is a topical oral agent used in the treatment of conditions resulting in reduced salivary flow such as xerostomia and hyposalivation caused by radiotherapy, mucositis, surgery, Sjögrens syndrome or obstruction of the salivary glands. Arcoral® Tab is characterized by high concentrations of calcium and phosphate ions, and lubricates the mucosa of the mouth, tongue and oropharynx and helps maintain the integrity of the oral cavity through its mineralizing potential. Arcoral® Tab has the same active ingredients as Caphosol® but comes in the more convenient formulation of an effervescent tablet to produce the mouth rinse.

EUSA Pharma intends to promote Arcoral® Tab directly through its specialist sales force in Europe, and through its international network of partners in a further 40 territories. EUSA also intends to submit the product for approval in the United States, and once approved to market it direct to specialists through the company's established US commercial infrastructure.

*"We are delighted to acquire the global rights to Arcoral® Tab, which is an ideal strategic fit with our portfolio of specialty medicines, and our focus on oncology and oncology supportive care," said **Lee Morley, EUSA Pharma's Chief Executive Officer**. "This next generation formulation represents an important advance on our existing Caphosol® product, and demonstrates EUSA's commitment to introducing next generation treatments to help specialists meet their patients' needs. As a recently established company, we have great ambitions for EUSA, and we look forward to accelerating our growth through the acquisition and in-licensing of further products that fit our specialty focus."*

*"EUSA Pharma, with its focus on oncology supportive care, is the perfect partner to ensure that patients across the world can benefit from our next generation formulation of Caphosol®," said **Björn Johansen, Arcoral Pharma's Chief Executive Officer**. "This advanced formulation is the result of many years of collaboration with scientists in Norway, Italy and the USA, and we now look forward to working with EUSA to make this important product available across the EU, US and further afield."*

- Ends -

About EUSA Pharma

Founded in March 2015, EUSA Pharma is a specialty pharmaceutical company with commercial operations in the US and Europe, and a wider distribution network in approximately 40 countries around the world. Currently, EUSA has a portfolio of five approved and several named-patient specialty hospital products, which the company has ambitious plans to expand through acquisition and in-licensing. EUSA is led by an experienced management team with a strong record of building successful specialty pharmaceutical companies, and is supported by significant funding raised from leading life science investor Essex Woodlands.

EUSA Pharma's products include: Caphosol® for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy; Collatamp®, a gentamicin-collagen implant licensed either in hemostasis or for the prevention and treatment of surgical site infection; Custodiol® solution for use in the preservation of organs for transplantation; Fomepizole® for the treatment of ethylene glycol poisoning; and Xenazine® for the treatment of movement disorders associated with Huntington's chorea. For more information please visit www.eusapharma.com.

Contacts

Lee Morley
Chief Executive
EUSA Pharma
Tel: +44 (0)330 5001140

Rob Budge
RJB Communications
Tel: +44 (0)1865 760969
Mobile: +44 (0)7710 741241